Adenovirus in solid organ transplant recipients

Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

on behalf of the AST Infectious Diseases Community of Practice

Research output: Contribution to journalArticle

Abstract

These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of adenovirus infections after solid organ transplantation. Adenovirus is an important cause of infectious complications in both stem cell transplant and SOT patients, causing a range of clinical syndromes including pneumonitis, colitis, and disseminated disease. The current update of the guidelines highlights that adenovirus surveillance testing should not be performed in asymptomatic recipients. Serial quantitative PCR might play a role in the decision to initiate or assess response to therapy in a symptomatic patient. The initial and most important components of therapy remain supportive care and decrease in immunosuppression. The use of antiviral therapy is not supported by prospective randomized clinical trials. However, intravenous cidofovir is considered the standard practice for treatment of severe, progressive, or disseminated adenovirus disease in most transplant centers. Intravenous immunoglobulin may be beneficial, primarily in a select group of patients with hypogammaglobulinemia. Future approaches to treatment of adenovirus disease may include administration of adenovirus-specific T-cell therapy.

Original languageEnglish (US)
Article numbere13527
JournalClinical Transplantation
DOIs
StatePublished - Jan 1 2019

Fingerprint

Adenoviridae
Communicable Diseases
Guidelines
Transplants
Adenoviridae Infections
Therapeutics
Agammaglobulinemia
Intravenous Immunoglobulins
Organ Transplantation
Colitis
Cell- and Tissue-Based Therapy
Immunosuppression
Antiviral Agents
Pneumonia
Stem Cells
Randomized Controlled Trials
Transplant Recipients
T-Lymphocytes
Polymerase Chain Reaction

Keywords

  • adenovirus
  • infection and infectious agents
  • infectious
  • solid organ transplant and transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Adenovirus in solid organ transplant recipients : Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. / on behalf of the AST Infectious Diseases Community of Practice.

In: Clinical Transplantation, 01.01.2019.

Research output: Contribution to journalArticle

@article{11c8ab99859741b99c2b8ebc56b07b83,
title = "Adenovirus in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice",
abstract = "These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of adenovirus infections after solid organ transplantation. Adenovirus is an important cause of infectious complications in both stem cell transplant and SOT patients, causing a range of clinical syndromes including pneumonitis, colitis, and disseminated disease. The current update of the guidelines highlights that adenovirus surveillance testing should not be performed in asymptomatic recipients. Serial quantitative PCR might play a role in the decision to initiate or assess response to therapy in a symptomatic patient. The initial and most important components of therapy remain supportive care and decrease in immunosuppression. The use of antiviral therapy is not supported by prospective randomized clinical trials. However, intravenous cidofovir is considered the standard practice for treatment of severe, progressive, or disseminated adenovirus disease in most transplant centers. Intravenous immunoglobulin may be beneficial, primarily in a select group of patients with hypogammaglobulinemia. Future approaches to treatment of adenovirus disease may include administration of adenovirus-specific T-cell therapy.",
keywords = "adenovirus, infection and infectious agents, infectious, solid organ transplant and transplantation",
author = "{on behalf of the AST Infectious Diseases Community of Practice} and Florescu, {Diana F} and Schaenman, {Joanna M.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/ctr.13527",
language = "English (US)",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Adenovirus in solid organ transplant recipients

T2 - Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice

AU - on behalf of the AST Infectious Diseases Community of Practice

AU - Florescu, Diana F

AU - Schaenman, Joanna M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of adenovirus infections after solid organ transplantation. Adenovirus is an important cause of infectious complications in both stem cell transplant and SOT patients, causing a range of clinical syndromes including pneumonitis, colitis, and disseminated disease. The current update of the guidelines highlights that adenovirus surveillance testing should not be performed in asymptomatic recipients. Serial quantitative PCR might play a role in the decision to initiate or assess response to therapy in a symptomatic patient. The initial and most important components of therapy remain supportive care and decrease in immunosuppression. The use of antiviral therapy is not supported by prospective randomized clinical trials. However, intravenous cidofovir is considered the standard practice for treatment of severe, progressive, or disseminated adenovirus disease in most transplant centers. Intravenous immunoglobulin may be beneficial, primarily in a select group of patients with hypogammaglobulinemia. Future approaches to treatment of adenovirus disease may include administration of adenovirus-specific T-cell therapy.

AB - These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of adenovirus infections after solid organ transplantation. Adenovirus is an important cause of infectious complications in both stem cell transplant and SOT patients, causing a range of clinical syndromes including pneumonitis, colitis, and disseminated disease. The current update of the guidelines highlights that adenovirus surveillance testing should not be performed in asymptomatic recipients. Serial quantitative PCR might play a role in the decision to initiate or assess response to therapy in a symptomatic patient. The initial and most important components of therapy remain supportive care and decrease in immunosuppression. The use of antiviral therapy is not supported by prospective randomized clinical trials. However, intravenous cidofovir is considered the standard practice for treatment of severe, progressive, or disseminated adenovirus disease in most transplant centers. Intravenous immunoglobulin may be beneficial, primarily in a select group of patients with hypogammaglobulinemia. Future approaches to treatment of adenovirus disease may include administration of adenovirus-specific T-cell therapy.

KW - adenovirus

KW - infection and infectious agents

KW - infectious

KW - solid organ transplant and transplantation

UR - http://www.scopus.com/inward/record.url?scp=85063720574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063720574&partnerID=8YFLogxK

U2 - 10.1111/ctr.13527

DO - 10.1111/ctr.13527

M3 - Article

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

M1 - e13527

ER -